Renaissance Technologies LLC recently announced the acquisition of new stake in NeuBase Therapeutics Inc. (NASDAQ:NBSE). The institutional investor has increased its shareholding in the Healthcare company by 8.01% to 0.38 million shares with purchase of 28276.0 shares. This fresh investment now brings its stake to 1.65% valued currently at $2.98 million. In addition, OrbiMed Advisors LLC raised its holdings by 0.37 million to 0.37 million shares. And EAM Investors LLC has lifted its position by 4.16% or 4152.0 shares – to 0.1 million shares.
With over 0.25 million NeuBase Therapeutics Inc. (NBSE) shares trading Tuesday and a closing price of $8.83 on the day, the dollar volume was approximately $2.16 million. The shares have shown a negative weekly performance of -0.67% and its price on 07/07/20 gained nearly 1.15%. Currently, there are 17.08M common shares owned by the public and among those 16.08M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: Several analysts who have offered their price forecasts for NBSE have a consensus price objective of $15.67. The analysts have set the share’s price value over the next 12 months at a high of $18.00 and a low of $13.00 should the stock experience a downside. Incidentally, analysts’ outlook for the NeuBase Therapeutics Inc. stock is 1.50 for the next 12 months. The estimated low will see the stock gain 32.08% over that period. But an upside of 50.94% will see the stock hit the forecast high price target while mean target price for the stock is $15.50.
Insiders at the company have transacted a total of 9 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 9 of these insider trades were purchases, accounting for 2,607,244 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in NeuBase Therapeutics Inc. are Biotech Growth Trust Plc (The), Vanguard Extended Market Index Fu, and Jacob Small Cap Growth Fund. Biotech Growth Trust Plc (The) owns 0.33 million shares of the company’s stock, all valued at over $2.56 million. The company bought an additional 0.33 million shares recently to bring their total holdings to about 1.42% of the shares outstanding. Vanguard Extended Market Index Fu has total holdings of 50394.0 shares valued at over $0.39 million and representing 0.22% of the shares outstanding. Jacob Small Cap Growth Fund sold 11000.0 shares to bring its total holdings to over 50000.0 shares at a value of $0.39 million. Jacob Small Cap Growth Fund now owns shares totaling to 0.22% of the shares outstanding.
Shares of NeuBase Therapeutics Inc. (NASDAQ: NBSE) opened at $8.73, down $0.0 from a prior closing price of $8.73. However, the script later closed the day at $8.83, up 1.15%. The company’s stock has a 5-day price change of -0.67% and 26.14% over the past three months. NBSE shares are trading 22.64% year to date (YTD), with the 12-month market performance up to 130.55% higher. It has a 12-month low price of $3.36 and touched a high of $11.78 over the same period. Currently, 0.25 million shares have been traded, compared to an average intraday trading volume of 417.57K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.54%, 3.09%, and 27.35% respectively.
Institutional ownership of NeuBase Therapeutics Inc. (NASDAQ: NBSE) shares accounts for 18.50% of the company’s 17.08M shares outstanding. Mutual fund holders own 2.29%, while other institutional holders and individual stakeholders account for 9.81% and 11.32% respectively.
It has a market capitalization of $204.68M and a beta (3y monthly) value of 0.46. The stock’s earnings-per-share (ttm) stands at -$3.19. The company has a Quick Ratio of 1.70 with the debt-to-equity ratio at 0.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.46% over the week and 9.42% over the month.
Analysts forecast that NeuBase Therapeutics Inc. (NBSE) will achieve an EPS of -$0.23 for the current quarter, -$0.22 for the next quarter and -$1 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.24 while analysts give the company a high EPS estimate of -$0.22. Comparatively, EPS for the current quarter was -$1 a year ago. Earnings per share for the fiscal year are expected to increase by 30.60%, and -5.30% over the next financial year. EPS over the next five years should compared to 16.90% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate NeuBase Therapeutics Inc. (NBSE) as a “Strong Buy” at a consensus score of 1.50. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 0 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the NBSE, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Outperform rating for the stock in a research note on June 16, 2020, with the firm’s price target at $16. Guggenheim coverage for the NeuBase Therapeutics Inc. (NBSE) stock in a research note released on February 07, 2020 offered a Buy rating with a price target of. Guggenheim was of a view on February 06, 2020 that the stock is Buy, while Oppenheimer gave the stock Outperform rating on November 21, 2019 $14. BTIG Research on their part issued Buy rating on September 24, 2019.